Navigation Links
VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
Date:10/5/2007

econd half of 2007. In addition, VioQuest and the U.S. Army are planning to submit a New Drug Application (NDA) to the U. S. Food and Drug Administration (FDA) in 2007 for Lenocta(TM) for the treatment of leishmaniasis.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. In addition, this press release also includes forward-looking statements regarding the timing, progress and results of the clinical development, regulatory processes, potential clinical trial initiations, potential IND and NDA filings and commercialization efforts of VioQuest's drug development product candidates. These statements are subject to various risks and uncertainties and include the possibility that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates, including Lenocta(TM), VQD-002, and Xyfid(TM) will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 3
'/>"/>

SOURCE VioQuest Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 Deerfield Management ... Healthcare Innovations Fund, L.P., which will invest in groundbreaking ... in genetic diseases, cancer, and orphan diseases. The venture ... transform how therapeutics are developed and improve the way ... one of the largest healthcare-focused venture funds in the ...
(Date:7/28/2015)... N.J. , July 28, 2015  Moerae ... second Phase 1 clinical trial with MMI-0100, a ... is being developed for pulmonary disorders characterized by ... United Kingdom , is a ... further evaluating the safety and tolerability of MMI-0100 ...
(Date:7/28/2015)... 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... has granted to German life sciences entrepreneurs with ... commercialization of biotechnology (collectively, the "Optionee"), an option ... tumor vaccine technology (the "Technology"), including AEZS-120, the ... is ready to enter a Phase 1 clinical ...
(Date:7/28/2015)... SINGAPORE , July 28, 2015  Faced ... treatments that are palliative rather than symptomatic, the ... With few existing therapies capable of curing or ... providers are starting to look towards regenerative medicine ... represents a new paradigm in human health with ...
Breaking Biology Technology:Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5
... of the equation , ,Identity theft has seen the ... three years. The United States is faced with an ever-changing ... both sides of the equation, organizational and consumer. , ... to a new report from the Federal Trade Commission (FTC). ...
... pioneer company looks to reclaim lost ground , ,CHIPPEWA FALLS, ... operating out of offices on Lowater Road here in its hometown, ... wonderful heights. , ,With its next-generation X1, on the market since ... toward the future with a twinkle in its corporate eye that, ...
... often been regarded as the economic motor of the European ... of Scandinavia, to the east of the U.K. and France, ... the east European countries of Poland, the Czech Republic and ... not only one of Europes largest populations but considering ...
Cached Biology Technology:Are You Ready for Identity Theft? 2Are You Ready for Identity Theft? 3Are You Ready for Identity Theft? 4Are You Ready for Identity Theft? 5Are You Ready for Identity Theft? 6Are You Ready for Identity Theft? 7Cray Rides Again 2Cray Rides Again 3German Life Science Oktoberfest Comes to the Midwest 2German Life Science Oktoberfest Comes to the Midwest 3German Life Science Oktoberfest Comes to the Midwest 4German Life Science Oktoberfest Comes to the Midwest 5German Life Science Oktoberfest Comes to the Midwest 6
(Date:7/23/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2015.  Revenue for ... of 33% compared to $6.8 million in the same quarter ... was $0.3 million, or $0.01 per diluted share, which compared ... same period a year ago.  Lower revenue ...
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... ARBOR, Mich.A new power scheme for cardiac pacemakers turns ... Engineering researchers at the University of Michigan designed ... heartbeats through the chest and converts it to electricity ... mini-medical machines send electrical signals to the heart to ...
... of the shark and are often removed from the body, which ... many countries allow the fins to be landed detached from shark ... cent of the total shark catch. New University of British Columbia ... A study published this week in the journal Fish ...
... are a rarely collected group of insects. Adults are considered ... of juvenile spiders. Eight genera are recorded in Australasia, including ... of large, hairy, often metallic coloured adults whose larvae specialize ... and funnel web spiders. In this study, four ...
Cached Biology News:Heart-powered pacemaker could one day eliminate battery-replacement surgery 2Law that regulates shark fishery is too liberal: UBC study 2
... observations of cell cultures under precise, controlled ... strain parameters in addition to a microscope ... chamber used by the ST-195 is compatible ... can be used with Nikon, Olympus, Leica, ...
... protein assay reagents package is used for determining ... and detergents. The RC DC protein assay is ... for 500 standard assays: 250 ml RC reagent ... alkaline copper tartrate solution, 2 L dilute Folin ...
... Kit is designed for concentration and ... samples. Proteomics sample analysis is often ... impurities such as buffers, salts and ... interfere with electrophoretic separations or enzymatic ...
... carrier proteins to simplify the production ... Carrier Proteins are commonly used carriers ... heterobifunctional cross-linker (Sulfo-SMCC). This activation results ... Thus allowing the maleimide-activated carrier ...
Biology Products: